Top sci­en­tists and BD ex­ecs craft Cul­li­nan, a $150 mil­lion R&D port­fo­lio shop fo­cused on can­cer

Close to six years ago, then Am­gen R&D chief Roger Perl­mut­ter told me he had been “car­ry­ing a torch for (CSO) Patrick Baeuer­le at Mi­cromet for a long time.” That ad­mi­ra­tion ex­plains why Perl­mut­ter was will­ing to pay more than a bil­lion dol­lars to buy Mi­cromet — where Baeuer­le was R&D chief — which even­tu­al­ly de­liv­ered the pi­o­neer­ing Blin­cy­to to the mar­ket.

Af­ter a stint at Am­gen, biotech be­ing the kind of project-fo­cused in­dus­try it’s be­come, Baeuer­le be­came a VC at MPM and a start­up mae­stro. And to­day he’s hav­ing a com­ing out par­ty for Cul­li­nan On­col­o­gy, an in­tense­ly project-ori­ent­ed biotech bankrolled with $150 mil­lion to set up a port­fo­lio of can­cer drugs to de­vel­op.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.